#clinical trials

Lead report

MapLight Therapeutics Q1 GAAP EPS -$1.32 Slightly Misses, CNS Pipeline in Focus

MapLight Therapeutics reported a Q1 GAAP loss of $1.32 per share, slightly wider than the expected $1.31 loss. Investors remain focused on the company's CNS pipeline progress and future funding plans.